Clinical Trials Logo

Filter by:
NCT ID: NCT05641324 Terminated - Multiple Myeloma Clinical Trials

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

NCT ID: NCT05641142 Recruiting - Clinical trials for Hereditary Hemorrhagic Telangiectasia

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

PROPLACO-Tel
Start date: April 7, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).

NCT ID: NCT05641116 Recruiting - Physical Activity Clinical Trials

Effectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis.

LyMouv'
Start date: September 14, 2023
Phase: N/A
Study type: Interventional

Lyme borreliosis, commonly known as Lyme disease, has been clinically described for more than a century, but has been officially recognized for 40 years, with the detection of the Borrelia bacterium by W. Burgdorfer, in ticks of the Ixodes ricinus complex, identified a few years before.

NCT ID: NCT05640960 Completed - Hepatic Sarcoma Clinical Trials

Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered

SARCOM
Start date: September 11, 2020
Phase:
Study type: Observational

Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age. Historically, it is a tumor treated only by surgery with a poor prognosis. In the last decade, the combination of more intensive chemotherapy and, more randomly, radiotherapy, has significantly improved the survival rate of these patients. Due to its low incidence, there are few series reported in the literature and to date there is no specific treatment protocol for the management of these tumors. It seems appropriate to review the management of these tumors in France in order to discuss the best therapeutic strategy.

NCT ID: NCT05640518 Recruiting - Renal Failure Clinical Trials

External Validation of the VExUS Score for the Prediction of Acute Renal Failure in Cardiac Surgery

ValiVexus
Start date: December 19, 2022
Phase:
Study type: Observational

Acute renal failure is a frequent complication associated with significant morbidity and mortality in postoperative cardiac surgery. The VExUS (Venous Excess UltraSound grading system) score was created to qualitatively assess this venous congestion, based on ultrasound data from patients obtained post operatively in cardiac surgery. These data included: inferior vena cava diameter, Doppler flow of the suprahepatic veins, portal trunk and renal veins. This score is predictive of the onset of acute renal failure in the first 3 days after surgery. The VExUS score has not been validated in an external and prospective way in cardiac surgery.

NCT ID: NCT05640388 Completed - Acne Clinical Trials

Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects

Start date: September 20, 2021
Phase:
Study type: Observational

The aim of the study is to understand the structural and functional modifications of the host, the microorganisms, and their interactions (host/microorganism relationship) before and after the RV3278A - ET0943 product application

NCT ID: NCT05640349 Completed - Bacteremia Clinical Trials

Evaluation of Bacteremia Epidemiology During the COVID Period in One French University Hospital

Start date: April 15, 2022
Phase:
Study type: Observational

The main objective of this retrospective cohort is to evaluate the impact of the first epidemic wave during lockdown on bacteremia epidemiology in one French University Hospital.

NCT ID: NCT05640141 Recruiting - Alzheimer Disease Clinical Trials

Pre-demential Motoric Cognitive Risk Syndrome in Ageing Subjects

PRESAGE
Start date: January 26, 2022
Phase:
Study type: Observational

The main aim of the study is to characterize and understand the pathological mechanisms underlying the motoric cognitive risk syndrome, which is a predictor of Alzheimer disease.

NCT ID: NCT05640128 Recruiting - Clinical trials for Hyperaldosteronism; Primary

Determination of Threshold Values of Aldosterone in HPLC-MS/MS, of Renin and of the Aldosterone / Renin Ratio for the Diagnosis of Primary Hyperaldosteronism

DAPS
Start date: January 2, 2018
Phase: N/A
Study type: Interventional

collaborative work within 2 hospitals at the CHU of Caen, at the CHRU of Lille, concerning the evaluation of the biological markers of primary hyperaldosteronism (PAH) with the dosage of aldosterone in LC -MS/MS, which is performed in both centers, with two different techniques. The main objective is to define the range of Aldosterone concentrations in LC MS/MS, of renin in an automated method, in populations of healthy volunteers, essential hypertensives, and hypertensives with primary hyperaldosteronism. , in order to establish a threshold for the screening of PAH by the RAR, and for the confirmation of PAH by a dynamic test with an Aldosterone threshold post salt load test.

NCT ID: NCT05640011 Completed - Breast Cancer Clinical Trials

Clinical Validation of an Artificial Intelligence Algorithm to Help Interpret Mammograms

ALGO-MAMMO
Start date: April 20, 2021
Phase:
Study type: Observational

This aims to clinically validate, on a large population, a tumor detection aid software which has already been trained on a representative French population (from several hospital centers and liberals from several departments in the west and east of France). This population consists of 1000 patients who have been treated for breast cancer (histologically proven by breast biopsy) and whose investigators have mammograms performed at the time of diagnosis. The control population consists of the unaffected breast of each patient (with the exception of the rare cases of bilateral cancers). This innovative software has the main feature of recognizing healthy breast tissue, allowing the radiologist to focus on breast tissue at risk, improving the management of medical time and the management of "difficult" files.